<DOC>
	<DOC>NCT00038935</DOC>
	<brief_summary>The purpose of this study is to determine the relative bioavailability of ReFacto AF as compared to ReFacto, when each is administered as 2-minute bolus infusions.</brief_summary>
	<brief_title>Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Severe hemophilia A (FVIII:C &lt; 1% at local laboratory) Previously treated patients (PTP) with at least 250 exposure days to any factor VIII product Age greater than or equal to 12 years\ The presence of any bleeding disorder in addition to hemophilia A Concomitant therapy with immunosuppressant drugs (e.g., intravenous immunoglobulin (IVIG), routine systemic corticosteroid use) History of detectable factor VIII inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Hemophilia</keyword>
</DOC>